The most common side effect of topical corticosteroid use is skin atrophy. All topical steroids can induce atrophy, but higher potency steroids, occlusion, thinner skin, and older patient age increase the risk. The face, the backs of the hands, and intertriginous areas are particularly susceptible. Resolution often occurs after discontinuing use of these agents, but it may take months. Concurrent use of topical tretinoin (Retin-A) % may reduce the incidence of atrophy from chronic steroid applications. 30 Other side effects from topical steroids include permanent dermal atrophy, telangiectasia, and striae.
Binding of an agent to the 3' cap of telomeric DNA can interfere with the telomerase enzyme and give the appearance of a telomerase inhibitor, providing a novel mechanism of action for anti-cancer therapy with interest to life extension.  Compounds that tend to associate with this target are large aromatic compounds with a polar charge,   and Berberine has been found to bind to this target with a 1:1 stoichiometric ratio with relatively high affinity;  which has preceded Berberine derivatives being synthesized for higher affinity.   Binding specificities for Berberine can be read here. 
Pharmacokinetic studies in men with Topicort® (desoximetasone) Ointment % with tagged desoximetasone showed no detectable level (limit of sensitivity: μg/mL) in 1 subject and and μg/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces . Seven days after application, no further radioactivity was detected in urine or feces. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.